tetano
Editor, Senior Moderator
Pathol Res Pract
. 2022 Dec 17;241:154280.
doi: 10.1016/j.prp.2022.154280. Online ahead of print.
Potential therapeutic applications of extracellular vesicles in the immunopathogenesis of COVID-19
Morteza Motallebnezhad[SUP] 1 [/SUP], Melodi Omraninava[SUP] 2 [/SUP], Hadi Esmaeili Gouvarchin Ghaleh[SUP] 3 [/SUP], Nematollah Jonaidi-Jafari[SUP] 1 [/SUP], Ali Hazrati[SUP] 4 [/SUP], Kosar Malekpour[SUP] 5 [/SUP], Yasser Bagheri[SUP] 6 [/SUP], Morteza Izadi[SUP] 7 [/SUP], Majid Ahmadi[SUP] 8 [/SUP]
Affiliations
Abstract
The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is the cause of coronavirus disease 2019 (COVID-19) which has emerged as a global health crisis. Recently, more than 50 different types of potential COVID-19 vaccines have been developed to elicit a strong immune response against SARS-CoV-2. However, genetic mutations give rise to the new variants of SARS-CoV-2 which is highly associated with the reduced effectiveness of COVID-19 vaccines. There is still no efficient antiviral agent to specifically target the SARS-CoV-2 infection and treatment of COVID-19. Therefore, understanding the molecular mechanisms underlying the pathogenesis of SARS-CoV-2 may contribute to discovering a novel potential therapeutic approach to the management of COVID-19. Recently, extracellular vesicle (EV)-based therapeutic strategies have received great attention on account of their potential benefits in the administration of viral diseases. EVs are extracellular vesicles containing specific biomolecules which play an important role in cell-to-cell communications. It has been revealed that EVs are involved in the pathogenesis of different inflammatory diseases such as cancer and viral infections. EVs are released from virus-infected cells which could mediate the interaction of infected and uninfected host cells. Hence, these extracellular nanoparticles have been considered a novel approach for drug delivery to mediate the treatment of a wide range of diseases including, COVID-19. EVs are considered a cell-free therapeutic strategy that could ameliorate the cytokine storm and its complications in COVID-19 patients. Furthermore, EV-based cargo delivery such as immunomodulatory agents in combination with antiviral drugs may have therapeutic benefits in patients with SARS-CoV-2 infection. In this review, we will highlight the potential of EVs as a therapeutic candidate in the diagnosis and treatment of COVID-19. Also, we will discuss the future perspectives regarding the beneficial effects of Evs in the development of COVID-19 vaccines.
Keywords: COVID-19; Extracellular vesicles; SARS-CoV-2; Therapeutics; Vaccine development.
. 2022 Dec 17;241:154280.
doi: 10.1016/j.prp.2022.154280. Online ahead of print.
Potential therapeutic applications of extracellular vesicles in the immunopathogenesis of COVID-19
Morteza Motallebnezhad[SUP] 1 [/SUP], Melodi Omraninava[SUP] 2 [/SUP], Hadi Esmaeili Gouvarchin Ghaleh[SUP] 3 [/SUP], Nematollah Jonaidi-Jafari[SUP] 1 [/SUP], Ali Hazrati[SUP] 4 [/SUP], Kosar Malekpour[SUP] 5 [/SUP], Yasser Bagheri[SUP] 6 [/SUP], Morteza Izadi[SUP] 7 [/SUP], Majid Ahmadi[SUP] 8 [/SUP]
Affiliations
- PMID: 36580795
- DOI: 10.1016/j.prp.2022.154280
Abstract
The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is the cause of coronavirus disease 2019 (COVID-19) which has emerged as a global health crisis. Recently, more than 50 different types of potential COVID-19 vaccines have been developed to elicit a strong immune response against SARS-CoV-2. However, genetic mutations give rise to the new variants of SARS-CoV-2 which is highly associated with the reduced effectiveness of COVID-19 vaccines. There is still no efficient antiviral agent to specifically target the SARS-CoV-2 infection and treatment of COVID-19. Therefore, understanding the molecular mechanisms underlying the pathogenesis of SARS-CoV-2 may contribute to discovering a novel potential therapeutic approach to the management of COVID-19. Recently, extracellular vesicle (EV)-based therapeutic strategies have received great attention on account of their potential benefits in the administration of viral diseases. EVs are extracellular vesicles containing specific biomolecules which play an important role in cell-to-cell communications. It has been revealed that EVs are involved in the pathogenesis of different inflammatory diseases such as cancer and viral infections. EVs are released from virus-infected cells which could mediate the interaction of infected and uninfected host cells. Hence, these extracellular nanoparticles have been considered a novel approach for drug delivery to mediate the treatment of a wide range of diseases including, COVID-19. EVs are considered a cell-free therapeutic strategy that could ameliorate the cytokine storm and its complications in COVID-19 patients. Furthermore, EV-based cargo delivery such as immunomodulatory agents in combination with antiviral drugs may have therapeutic benefits in patients with SARS-CoV-2 infection. In this review, we will highlight the potential of EVs as a therapeutic candidate in the diagnosis and treatment of COVID-19. Also, we will discuss the future perspectives regarding the beneficial effects of Evs in the development of COVID-19 vaccines.
Keywords: COVID-19; Extracellular vesicles; SARS-CoV-2; Therapeutics; Vaccine development.